Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

Unichem: Strong growth

Jun 20, 2002

A wider therapeutic reach, increasing presence in exports and restructuring benefits have helped Unichem Labs display robust numbers for FY02. The company's margins have shown steady improvement in the last two years due to product introductions in high growth segments. The company ended FY02 with a 55% growth in net profits.

Kopran: Lacks future clarity

Jan 3, 2002

Recently, Kopran sold its top selling Cardiovascular ‘Aten’ brand to Cadila for a consideration of Rs 950 m. The company is also believed to be in talks with other pharmaceutical majors for the sale of its remaining formulation business. Kopran seems to trying to change the perception and business profile to that of a company focused purely on the OTC segment. So far the company has met with initial success with its brand ‘Smyle’.

Unichem: Restructuring pays off

Sep 21, 2001

The restructuring exercise initiated by Unichem Laboratories seems to be bearing fruit. The company's margins have shown steady improvement in the last two years due to high margin product introductions and increasing focus on exports. The company's domestic formulations business grew by a robust 22.8% last fiscal.

Kopran: Uncertain Future

Sep 6, 2001

Kopran, promoted by Parijat Enterprise, is one of the integrated domestic pharmaceutical players. Its products Aten (cardiovascular), Vent (respiratory) and Smyle enjoy strong brand equity. The company is in the midst of business and financial restructuring. The company is trying to change the perception and business profile from that of a commodity bulk manufacturer and supplier to a formulations based company with an ability to create strong brands.

Interest reduction, other income boost bottomline

Jan 20, 2000

Unichem has reported an impressive growth in earnings by 47.3%. The turnover has improved by 3.6% as compared to the third quarter last year and the company has managed to control rise in expenditure to 5%. Overall, formulation sales are under pressure and Unichem is no exception to the general trend in the pharmaceutical sector. The growth in bottomline has been led by the reduction in the interest costs.

Unichem Labs posts 35.7% jump in net

Oct 26, 1999

Unichem Labs sales (Rs 564 m) appreciated 8.7% in 2QFY2000. A 35.7% leap in net profit effected a rise in net profit margin to 8.7% (6.9%).


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS